Literature DB >> 16888407

Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients.

L Desjardins1, L Lumbroso-Le Rouic, C Levy-Gabriel, R Dendale, S Delacroix, C Nauraye, M Estève, C Plancher, B Asselain.   

Abstract

INTRODUCTION: Exudation from the tumour scar and glaucoma can be major problems after proton beam irradiation of uveal melanoma and can sometimes lead to secondary enucleation. We conducted a randomized study to determine whether systematic transpupillary thermotherapy (TTT) after proton beam radiotherapy could have a beneficial effect. PATIENTS AND
METHOD: Between February 1999 and April 2003, all the patients treated by proton beam radiotherapy for uveal melanomas >/=7 mm thick or >/=15 mm in diameter were included in this study after giving their informed consent. One half of the patients received proton beam radiotherapy alone (60 Gy in 4 fractions) and the other half received the same dose of proton beam radiotherapy followed by TTT at 1, 6 and 12 months. All the information concerning the initial tumour parameters, treatments and follow-up was recorded and a statistical analysis was performed.
RESULTS: We randomized 151 patients. The median follow-up was 38 months. The 2 groups of patients were similar in terms of age, gender and tumour characteristics. The patients treated with TTT showed a greater reduction of tumour thickness (p = 0.06), less retinal detachment at the latest follow-up (p = 0.14) and a lower secondary enucleation rate (p = 0.02). DISCUSSION: The present study is the first randomized analysis to demonstrate a significant decrease in the secondary enucleation rate in patients treated with TTT after proton beam radiotherapy. Further studies should be performed to determine whether TTT could be beneficial to smaller tumours and to define its optimal dose. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888407     DOI: 10.1159/000094834

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  10 in total

1.  Proton beam therapy: the next disruptive innovation in healthcare?

Authors:  Samuel Swisher-McClure; Stephen M Hahn; Justin Bekelman
Journal:  Postgrad Med J       Date:  2015-05       Impact factor: 2.401

2.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

Review 3.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

Review 4.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

5.  Current molecular and clinical insights into uveal melanoma (Review).

Authors:  Matteo Fallico; Giuseppina Raciti; Antonio Longo; Michele Reibaldi; Vincenza Bonfiglio; Andrea Russo; Rosario Caltabiano; Giuseppe Gattuso; Luca Falzone; Teresio Avitabile
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

6.  Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.

Authors:  James P Bolling; Roi Dagan; Michael Rutenberg; Maria Mamalui-Hunter; Steven J Buskirk; Michael G Heckman; Alexander P Hochwald; Roelf Slopsema
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-12-22

Review 7.  Non-Cancer Effects following Ionizing Irradiation Involving the Eye and Orbit.

Authors:  Juliette Thariat; Arnaud Martel; Alexandre Matet; Olivier Loria; Laurent Kodjikian; Anh-Minh Nguyen; Laurence Rosier; Joël Herault; Sacha Nahon-Estève; Thibaud Mathis
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

8.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

9.  The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.

Authors:  Hua Yang; Craig M Brackett; Vanessa Marie Morales-Tirado; Zezhong Li; Qing Zhang; Matthew W Wilson; Camille Benjamin; Wayne Harris; Edmund K Waller; Andrei V Gudkov; Lyudmila G Burdelya; Hans E Grossniklaus
Journal:  Oncotarget       Date:  2016-01-19

10.  Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy.

Authors:  Mercy Ofuya; Lucy McParland; Louise Murray; Sarah Brown; David Sebag-Montefiore; Emma Hall
Journal:  Clin Transl Radiat Oncol       Date:  2019-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.